Read More Analyst Ratings News Price Target Citigroup Maintains Buy on AT&T, Raises Price Target to $22 By Benzinga Newsdesk January 24, 7:35 AM Citigroup analyst Michael Rollins maintains AT&T (NYSE:T) with a Buy and raises the price target from $20 to $22. T
Read More Asset Sales Biotech Equities General Guidance Health Care M&A Markets News UnitedHealth’s Decision To Sell Its Operations In Brazil To A Private Investor Leads To $7B Charge – What’s On The Cards? By Nabaparna Bhattacharya December 29, 11:23 AM UnitedHealth Group Incorporated (NYSE: UNH) disclosed on Friday that it has entered into an UNH
Read More News SmileDirectClub Says On Nov. 18, 2022 Co. Received Letter From Nasdaq Indicating Failure To Satisfy Continued Listing Rule By Michael Horton November 23, 5:25 PM -Reuters SDC
Read More News Why Lexaria Bioscience (LEXX) Shares Are Moving By Henry Khederian February 15, 10:27 AM Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering. LEXX